May 11, 2026 — CanSino Biologics Inc. ("CanSinoBIO"; SHSE: 688185, HKEX: 06185) announced today that its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (for people aged six years old and above) (the "Td5cp Adolescent and Adult")—has been formally granted Priority Review status by China's National Medical Products Administration (NMPA).

The designation marks another important milestone in CanSinoBIO's strategy to build a life-course pertussis immunization portfolio. The vaccine candidate is expected to help address the unmet need for booster immunization against pertussis among older children, adolescents, and adults in China, supporting broader and more durable population protection.

Pertussis, or whooping cough, is a highly contagious respiratory disease caused by Bordetella pertussis¹. In recent years, the disease has experienced a global resurgence. In China alone, reported pertussis cases exceeded 470,000 in 2024¹, representing an approximately 12-fold increase compared with 2023, drawing heightened public health attention.

In response to the evolving epidemiological landscape, booster immunization beyond infancy has become increasingly important. While vaccination remains one of the most effective measures to prevent pertussis, China has long lacked a dedicated pertussis-containing booster vaccine for populations aged six years and above. CanSinoBIO's Td5cp Adolescent and Adult was designed to help expand pertussis protection across broader age groups.

In April 2026, CanSinoBIO's Diphtheria, Tetanus and Pertussis (Acellular, Three Components) Combined Vaccine, Adsorbed for infants (below 2 years old) (the "DT3cP Infant"), Tripecia® received approval through the NMPA's Priority Review pathway, representing an important breakthrough in China's advancement of component-based pertussis vaccine technologies.

Compared with the three-component (PT, FHA, PRN) DT3cP vaccine, the company's five-component Td5cp Adolescent and Adult includes two additional pertussis antigens, FIM2 and FIM3. Each pertussis antigen is individually purified and formulated at precise ratios, helping enhance manufacturing consistency and overall product quality.

With the Td5cp Adolescent and Adult entering the Priority Review pathway, CanSinoBIO is accelerating the development of its pertussis vaccine portfolio. Together with the approved DT3cP vaccine Tripecia®, the candidate is expected to contribute to a broader life-course immunization strategy spanning infants, adolescents, and adults.

The company continues to focus on unmet needs in infectious disease prevention, advancing innovation across key disease areas including meningitis, pneumonia and pertussis. Leveraging multiple technology platforms, it is strengthening the integrated vaccine R&D and manufacturing capabilities with a focus on innovative bacterial vaccines. Looking ahead, CanSinoBIO will further enhance its life-course immunization portfolio and advance the development of innovative vaccine solutions to support infectious disease prevention and broader public health needs.

Disclaimer:

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

References:

1.中国疾控中心：

https://www.chinacdc.cn/jkyj/mygh02/jbzt/xjxcrb/brk/202409/t20240925_300997.html